Lipid disorders contributing to coronary heart disease: An update

Current Problems in Cardiology

Volumn 21, Issue 11, 1996, Pages 734-780

  Robert Superko, H ^a  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANGIOCARDIOGRAPHY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; HUMAN; HYPERLIPIDEMIA; REVIEW; RISK;

CHOLESTEROL, LDL; CLINICAL TRIALS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; COST-BENEFIT ANALYSIS; HOMOCYSTEINE; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEIN(A); RISK;

EID: 0030277145     PISSN: 01462806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Superko HR. Failure of cholesterol treatment in CAD patients: a cost effective solution. Am J Cardiol 1995;75:277.
2. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham study. Ann Intern Med 1979;90:85-91.
3. Genest JJ, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature CAD. Circulation 1992;85:20205-33.
4. Superko HR. New aspects of cardiovascular risk factors including small, dense LDL, homocysteinemia, and Lp(a). Curr Opin Cardiol 1995;10:347-54.
5. Superko HR, Krauss RM. Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994;90:1056-69.
6. Carlson LA, Danielson M, Ekberg I, Klintemar B, Rosenhamar G. Reduction of myocardial re-infarction by the combined treatment with clofibrate and nicotinic acid. Atherosclerosis 1977;28:81-6.
7. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acts Med Scand 1988;223:405-18.
8. Coronary Drug Project Research Group. Natural history of myocardial infarction in the coronary drug project: long-term prognostic importance of serum lipid levels. Am J Cardiol 1978;42:489-98.
9. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
10. Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results: I. Reduction in incidence of coronary heart disease, and II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:351-74.
11. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-45.
12. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;349:1383-9.
13. Shepherd J, Cobbe SM, Isles CG, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
14. Pfeffer M. Symposia 610: Major clinical trials III: Medical therapy to prevent complications of acute ischemia: the CARE Trial: American College of Cardiology Annual Meeting 1996. J Am Coll Cardiol 1996;27:xiii.
15. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park JS, McGovern ME, PLAC I Investigators. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I). J Am Coll Cardiol 1995;26:1133-9.
16. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-8.
17. Superko HR, Wood PD, Krauss RD. Effect of alpha- and selective beta-blockade for hypertension control on plasma lipoproteins, apoproteins, lipoprotein subclasses, and postprandial lipemia. Am J Med 1989;86(Suppl 1B):26-31.
18. Jukema JW, Bruschke VG, van Boven AJ, et al. and REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels (REGRESS). Circulation 1995;91:2528-40.
19. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients (HARP). Lancet 1994;344:1182-6.
20. Campos CT, Nguyen P, Buchwald, and the POSCH Group. Effect of cholesterol lowering on PTCA, CABG, and heart transplantation rates: POSCH long-term follow-up study. Circulation 1993;88:1-386.
21. Alderman EL, Haskell WL, Fair JM, et al. Beneficial angiographie and clinical response to multifactor modification in the Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89:975-90.
22. Stewart BR, Brown BG, Shao XQ, et al. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J Am Coll Cardiol 1994;23:899-906.
23. Waters D, Hollyer J, Thompson GR. What should be the goal of LDLC lowering in coronary patients: a fixed level or a percent reduction? [Abstract] J Am Coll Cardiol 1996;27:133A.
24. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
25. Goldbourt U, de Faire U, Berg K. Genetic factors in coronary heart disease. Bingham, MA: Kluwer Academic Publishers, 1994.